Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everytime I see this commercial, I think of this stock,
Why are you so rude.?.Anyone posting on this board always has to deal with your derogatory remarks..Maybe your the one with an agenda..
PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION JUNE 15, 2010
The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and neither we nor the selling stockholders are soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
PROSPECTUS
MEDCLEAN TECHNOLOGIES, INC.
26,995,331 Shares of Common Stock
This Prospectus relates to the resale of up to 26,995,331 shares of our common stock to be offered by the selling stockholders consisting of (i) 20,298,666 unissued shares of our common stock to be offered for resale by selling stockholders upon the exercise of outstanding common stock purchase warrants issued to certain investors in the Company and (ii) 6,696,665 unissued shares of our common stock to be offered for resale by selling stockholders upon exercise of common stock options issued to certain employees of the Company.
The selling stockholders may sell Common Stock from time to time in the principal market on which the stock is traded at the prevailing market price or in negotiated transactions. See “Plan of Distribution” which begins on page 28.
We will not receive any of the proceeds from the sale of Common Stock by the selling stockholders. However, we will generate proceeds from the cash exercise of the warrants by the selling stockholders, if any. We intend to use those proceeds for general corporate purposes. We will pay the expenses of registering these shares.
Our common stock is quoted on the Over-the-Counter Bulletin Board and trades under the symbol “MCLN.” The last reported sale price of our common stock on the Over-the-Counter Bulletin Board on June 15, 2010, was approximately $.0166 per share.
We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.
Brokers or dealers effecting transaction in the securities should confirm the registration of these securities under the securities laws of the states in which transactions occur or the existence of our exemption from registration.
YOU SHOULD CONSIDER CAREFULLY THE RISKS ASSOCIATED WITH INVESTING IN OUR COMMON STOCK. BEFORE MAKING AN INVESTMENT, PLEASE READ THE “RISK FACTORS” SECTION OF THIS PROSPECTUS, WHICH BEGINS ON PAGE 5.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
http://ih.advfn.com/p.php?pid=nmona&article=43249038&symbol=NB%5EMCLN
ironhammer, Thanks for going the extra mile.
This will help some to better understand.!!
http://www.businessjive.com/
Good DD does take alot of time to compile and verify. You seem to do it very well. Thanks for all your time,effort and research. Much appreciated !!
JULY 24 2010 @ 3:22 pm
Thanks abbytraderwin
Very Interesting; A must Watch for some http://www.businessjive.com/
Found on youtube, its shows how the system works.
http://www.sec.gov/foia/docs/failsdata.htm
Frequently Requested FOIA Document:
Fails-to-Deliver Data
What You Should Know About the Data
This text file contains the date, CUSIP numbers, ticker symbols, issuer name, price, and total number of fails-to-deliver (i.e., the balance level outstanding) recorded in the National Securities Clearing Corporation's ("NSCC") Continuous Net Settlement (CNS) system aggregated over all NSCC members. Data prior to July 1, 2009 include only securities with a balance of total fails-to-deliver of at least 10,000 shares as of a particular settlement date. Data on or after July 1, 2009 include all securities with a balance of total fails-to-deliver as of a particular settlement date. The data include fails-to-deliver in equity securities.
The values of total fails-to-deliver shares represent the aggregate net balance of shares that failed to be delivered as of a particular settlement date. If the aggregate net balance of shares that failed to be delivered is less than 10,000 as of a particular settlement date prior to July 1, 2009, then no record will be present in the file for that date even if there are fails in that security. If the aggregate net balance of shares that failed to be delivered is zero as of a particular settlement date on or after July 1, 2009, then no record will be present in the file for that date. Fails to deliver on a given day are a cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day. The figure is not a daily amount of fails, but a combined figure that includes both new fails on the reporting day as well as existing fails. In other words, these numbers reflect aggregate fails as of a specific point in time, and may have little or no relationship to yesterday's aggregate fails. Thus, it is important to note that the age of fails cannot be determined by looking at these numbers. In addition, the underlying source(s) of the fails-to-deliver shares is not necessarily the same as the underlying source(s) of the fails-to-deliver shares reported the day prior or the day after.
Data Prior to July 2009
Prior to July 2009, the files contain each settlement date over a calendar month. The monthly files are archived in a zipped file for each calendar quarter. We cannot guarantee the accuracy of the data.
Data Starting July 2009
Starting July 2009, each month is contained in two files. The first half of a given month is available at the end of the month. The second half of a given month is available at about the 15th of the next month. We cannot guarantee that the data will be posted by a particular date. We cannot guarantee the accuracy of the data.
The price field includes the closing price of the security on the previous day as long as the price is available and is greater than one penny. When the price is not available or is less than a penny, the field is filled with a “.”. Even when prices are included in the data, we cannot guarantee that this price matches closing prices available from other sources.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, and are not evidence of abusive short selling or “naked” short selling. For more information on short selling and fails-to-deliver, see http://www.sec.gov/spotlight/keyregshoissues.htm, http://www.sec.gov/divisions/marketreg/mrfaqregsho1204.htm, and http://www.sec.gov/rules/final/34-50103.htm.
What You Should Know About the Data File
The information in this file is raw data — data that are meant to be used as input to another program. The data items are provided as a "pipe delimited" text file. Although the file can be viewed in any program that accepts ASCII text (for example, a word processor), the data fields are best viewed when imported into a program that accepts delimited data, such as a spreadsheet or a statistical application. The record layout and maximum field sizes are shown below for those who want to process the data into another form.
Field Name Field Description Maximum Size
SETTLEMENT DATE SETTLEMENT DATE Number - 8 digits
CUSIP CUSIP 9 characters
SYMBOL TICKER SYMBOL 10 characters
QUANTITY (FAILS) TOTAL FAILURE-TO-DELIVER SHARES Number - unlimited
DESCRIPTION COMPANY NAME 30 characters
PRICE CLOSING PRICE ON PREVIOUS DAY Number - unlimited
For technical questions regarding the website, send an e-mail message to webmaster@sec.gov. For additional information about the data, call the SEC's Office of Freedom of Information and Privacy Act Operations at (202) 551-7900.
Current Data
Download the Current Fails-to-Deliver Data
Report for the second half of November 2009
Archive Data
A Renewed Sense of Optimism in Paradigm Medical (OTC:PDMI.PK)
Submitted By StocksHaven
The Medical device industry has been one of the most successful industries within 2008 and 2009, and 2010 should continue that trend. StocksHaven Investments profiles Paradigm Medical Industries, Inc., a promising company who will soon begin to introduce the first of its four new ophthalmic diagnostic devices, the Paravue, during the remainder of 2009. Plagued by lawsuits, financial woes, and poor management — the company has made a vast array of changes during late 2008 and 2009 leading to an invigorated interest in past and present shareholders. The company named Stephen Davis the new president, an individual with an impeccable ability to attain funds and grants for struggling institutions, alongside 20 years experience in the ophthalmic industry. Paradigm also has the only patented technology utilizing photon lasers for cataract removal and is poised to capture a niche market within the glaucoma and ultrasound microscopy fields. The glaucoma market alone is estimated to reach $4 billion in 2010. With a portfolio consisting of a total of 15 devices currently available, and 4 pending release with one expect by end of 2009, Paradigm seems to have positioned itself nicely for a rebound in the near future.
About Paradigm Medical Industries, Inc.
Paradigm Medical Industries, Inc. develops, manufactures, sources, markets and sells ophthalmic surgical and diagnostic instrumentation and related accessories, including disposable products. The Company’s surgical equipment is designed for minimally invasive cataract treatment. Its cataract removal system, the Photon laser system, is a laser cataract surgery system designed to be marketed as the next generation of cataract removal. The Company’s diagnostic products include a P2000 pachymetric analyzer, a P37 Ultrasonic A/B Scan, P40, P45 and P60 UBM Ultrasound Biomicroscopes, a P37 A/B Scan, two perimeters, the Blood Flow Analyzer, and the Glaid. The diagnostic ultrasonic products, including the P2000 pachymetric analyzer, the P37 Ultrasonic A/B Scan and the P40 UBM Ultrasound Biomicroscope were acquired from Humphrey Systems, a division of Carl Zeiss.
http://www.bestwaytoinvest.com/stories/a-renewed-sense-optimism-paradigm-medical-otcpdmipk